3-(Aminomethyl)-5-methylhexanoic acid

We are 3-(Aminomethyl)-5-methylhexanoic acid CAS:128013-69-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-(Aminomethyl)-5-methylhexanoic acid
CAS.NO:128013-69-4
Synonyms:
3-AMINOMETHYL-5-METHYLHEXANOIC ACID
PREGABALIN
rac-Pregabalin
(+-)-3-(aminomethyl)-5-methylhexanoic acid
(RS)-3-AMINOMETHYL-5-METHYL-HEXANOIC ACID
()-PREGABALIN
RAC PREGABALIN
HEXANOIC ACID,3-(AMINOMETHYL)-5-METHYL-

Molecular Formula: C8H17NO2
Molecular Weight: 159.22600

Physical and Chemical Properties:
Density: 0.997g / cm3
Boiling point: 274ºC at 760 mmHg
Melting point: 148-150ºC
Flash point: 119ºC
Refractive index: 1.465

Specification:
Appearance: White crystalline powder
Purity:≥99%
Moisture Content: ≤0.1%
Impurity: ≤0.5%
Residue on Ignition: 0.1% Max
Heavy Metal: 10 ppm Max

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Pregabalin CAS:148553-50-8

Related News: Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.2,2-dimetil-4H-pirido [3,2-b] [1,4] oxazin-3-ona CAS:20348-21-4 The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.62162-97-4 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.27329-70-0 According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth.